US Patent Issued to AstraZeneca on Sept. 9 for "Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases" (Swedish Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,409,174, issued on Sept. 9, was assigned to AstraZeneca AB (Sodertalje, Sweden).

"Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases" was invented by Peter Greasley (Molndal, Sweden), Christine Ahlstrom (Molndal, Sweden), Stanko Skrtic (Molndal, Sweden), Robert Menzies (Molndal, Sweden), Anne-Kristina Mercier (Molndal, Sweden) and Mikael Sunnaker (Molndal, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatm...